Skip to main content
SpringerLink
Log in

Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Downregulation of glucose and fatty acid oxidation occurs in heart failure (HF). Trimetazidine reduces fatty acid oxidation and increases glucose oxidation. In this single-blind study, trimetazidine, 20 mg three times per day (n = 51) or placebo (n = 36) was added to treatment of 87 HF patients receiving optimal HF therapy. Etiology of heart failure was coronary artery disease in 35 patients (68.6%) in the trimetazidine group and 22 (62.9%) in the placebo group. Fourteen (27.5%) patients in the trimetazidine group and 11 (31.4%) patients in the placebo group had diabetes. Peak systolic velocity (Vs), and the peak early diastolic (Vd) and late diastolic (Va) velocities of various segments left and right ventricles (RV) were obtained with tissue Doppler imaging (TDI) and averaged. Patients were re-evaluated three months later. Significant increases in mean left ventricular ejection fraction (LVEF) (33.3% ± 5.6% to 42.4% ± 6.3%, P < 0.001 and 30.6% ± 8.2% to 33.2% ± 6.6%, P = 0.021) and LV and RV myocardial velocities and mitral and tricuspid annular TDI velocities were observed in both groups. However, compared to placebo, increments in LVEF (9.1% ± 4.2% vs. 2.5% ± 1.4%, P < 0.001) and myocardial velocities were significantly higher with trimetazidine (P < 0.001 for LV Vs, Vd, Va; P = 0.035 for RV Vd; and P < 0.001 for RV Va and Vs). Increase in LVEF with trimetazidine was significantly correlated with presence of diabetes (r = 0.524, P < 0.001). With trimetazidine LVEF increased significantly more in diabetic patients compared to nondiabetics (P < 0.001). Also, patients having both diabetes and ischemic HF tended to have greater improvement in LVEF compared to ischemic HF patients without diabetes (P = 0.063). Addition of trimetazidine to current treatment of HF, especially for those who are diabetic, may improve LV and RV functions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lopaschuk GD, Stanley WA, Lopaschuk CC (2005) Metabolic approach in heart failure: the rationale for metabolic interventions. Heart Metab 27:5–10

    Google Scholar 

  2. Stanley WC, Chandler MP (2002) Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7:115–130

    Article  CAS  PubMed  Google Scholar 

  3. Kantor PF, Lucien A, Kozak R, Lopaschuk GD (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by mitochondrial longchain 3-ketoacyl coenzyme A thiolase. Circ Res 86:580–588

    CAS  PubMed  Google Scholar 

  4. Lopaschuk GD, Barr R, Thomas PD, Dyck JR (2003) Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:33–37

    Article  Google Scholar 

  5. Brottier L, Barat L, Combe C, Boussens B, Bonnet J, Bricaud H (1990) Therapeutic value of a cardio protective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 11:207–212

    CAS  PubMed  Google Scholar 

  6. Lu C, Dabrowski P, Fragasso G, Chierchia SL (1998) Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease: a double-blind, placebo-controlled, crossover study. Am J Cardiol 82:898–901

    Article  CAS  PubMed  Google Scholar 

  7. Belardinelli R, Purcaro A. (2001) Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 22:2164–2170

    Article  CAS  PubMed  Google Scholar 

  8. Di Napoli P, Taccardi AA, Barsotti A (2005) Long term cardioprotective action of trimetazidine and potential effects on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 91:161–165

    Article  PubMed  Google Scholar 

  9. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM (2004) Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25:1814–1821

    Article  CAS  PubMed  Google Scholar 

  10. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A (2003) Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146:E18

    Article  CAS  PubMed  Google Scholar 

  11. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M (2003) Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 28;2:16

    Article  Google Scholar 

  12. Nagueh SF, Middleton K, Kopelen H, Zoghbi WA, Quinones MA (1997) Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressure. J Am Coll Cardiol 30:1527–1533

    Article  CAS  PubMed  Google Scholar 

  13. Gulati VK, Katz WE, Follansbee WP, Gorcsan J (1996) Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 77: 979–984

    Article  CAS  PubMed  Google Scholar 

  14. Yamazaki N, Mine Y, Sano A, Uematsu M, Yamazaki N, Mine Y, Sano A, Hirama M (1994) Analysis of ventricular wall motion using color-coded tissue Doppler imaging system. Jpn J Appl Phys 33:3141–3146

    Article  Google Scholar 

  15. Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, Lam PK, Sanderson JE (2003) Peak early mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol 41:820–826

    Article  PubMed  Google Scholar 

  16. Sogaard P, Egeblad H, Kim WY, Jensen HK, Pedersen AK, Kristensen BO, Mortensen PT (2002) Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. J Am Coll Cardiol 40:723–730

    Article  PubMed  Google Scholar 

  17. Terzi S, Sayar N, Bilsel T, Enc Y, Yildirim A, Ciloglu F, Yesilcimen K (2007) Tissue Doppler imaging adds incremental value in predicting exercise capacity in patients with congestive heart failure. Heart Vessels 22:237–244

    Article  PubMed  Google Scholar 

  18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiography 18:1440–1463

    Article  Google Scholar 

  19. Cooke GA, Marshall P, al-Timman JK, Wright DJ, Riley R, Hainsworth R, Tan LB (1998) Physiological cardiac reserve: development of a non-invasive method and first estimates in man. Heart 79:289–294

    CAS  PubMed  Google Scholar 

  20. Marzilli M (2003) Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 19:661

    Article  CAS  PubMed  Google Scholar 

  21. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A (2007) A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48:992–998

    Article  CAS  PubMed  Google Scholar 

  22. Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol 62: 493–499

  23. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S (2005) Effects of Trimetazidine on myocardial perfusion and contractile response of electronically dysfunctional myocardium in ischaemic cardiomyopathy. Am J Cardiovasc Drugs 5:271–278

    Article  CAS  PubMed  Google Scholar 

  24. Di Napoli P, Di Giovanni P, Gaeta MA, D’Apolito G, Barsotti A (2007) Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 154:602.e1–e5

    Article  Google Scholar 

  25. Taegtmeyer H (1994) Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 19:59–113

    Article  CAS  PubMed  Google Scholar 

  26. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R (2002) Metabolic approaches to the treatment of ischemic heart disease: The clinicians’ perspective. Heart Fail Rev 7:187–203

    Article  CAS  PubMed  Google Scholar 

  27. Rodriques B, Cam MC, McNeill JH (1998) Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180:53–57

    Article  Google Scholar 

  28. Galrinho A, Branco L, Soares R, Timoteo A, Abreu J, Leal A, Silva S, Ferraira R (2006) Prognostic implications of tissue Doppler in patients with dilated cardiomyopathy. Rev Port Cardiol 25: 797–798

    Google Scholar 

  29. Meluzin J, Spinarova L, Bakala J, Toman J, Krejcí J, Hude P, Kara T, Soucek M (2001) Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 22:280–282

    Article  Google Scholar 

  30. Sengupta R, Patel R, Dokainish H (2006) Right ventricular tissue Doppler is an independent predictor of outcome in patients with left ventricular heart failure. J Am Soc Echocardiogr 19:624a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Department, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey

    Yilmaz Gunes, Unal Guntekin, Mustafa Tuncer & Musa Sahin

Authors
  1. Yilmaz Gunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Unal Guntekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mustafa Tuncer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Musa Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yilmaz Gunes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gunes, Y., Guntekin, U., Tuncer, M. et al. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 24, 277–282 (2009). https://doi.org/10.1007/s00380-008-1118-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-008-1118-x

Key words

Search

Navigation